The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) was established in 2005. It was formed by a collaborative group of researchers working on genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers.
The aim of CIMBA is to provide sufficient sample sizes to allow large scale studies in order to evaluate reliably the effects of genetic modifiers.
Currently, the Consortium consists of over 70 different study groups, incorporating sites from Europe, North and South America, Australia, Asia and Africa. We have phenotype data for over 46,000 BRCA1 and BRCA2 mutation carriers and DNA samples for about 38,000. These numbers are constantly increasing with the incorporation of new groups.
CIMBA Coordination & Funding
Coordination of CIMBA is through the University of Cambridge and the QIMR Berghofer Medical Research Institute and, along with analytical efforts, is funded by Cancer Research UK (CRUK) and the National Health and Medical Research Council of Australia (NHMRC) .
CIMBA is supported by funding from Cancer Research UK programme grant (12292/A20861): Development of risk prediction models for breast, ovarian, prostate and other cancers